



Norgine announces a 10% increase in sales for 2005

30 January 2006

Norgine, the European Specialty Pharmaceutical company, today announced sales of €171m in 2005, an increase of 10% over 2004. This is the nineteenth consecutive year of double-digit growth for the company.

Sales growth was led by Movicol®, the leading European prescription product for the treatment of chronic constipation and faecal impaction in adults and children. In 2005 Movicol® saw a 24% increase in sales.

Commenting on the figures Peter Stein, Chief Executive Officer said “As we enter our centenary year, it is excellent to report that 2005 represented another highly successful year for Norgine”.

ENDS

Notes to editor

Norgine is an independent, successful European specialty pharmaceutical company that has been established for 100 years and has a presence in all the major European markets. The company employs over 900 people, of which 350 are in sales and marketing.

Norgine’s current focus is pharmaceutical products that address significant unmet clinical need in areas such as gastroenterology, hepatology and pain management. The company currently markets a range of products in its key therapeutic areas e.g. Movicol® for the treatment of chronic constipation and faecal impaction, Klean-Prep® for bowel preparation prior to colonoscopy, and Oramorph® for the treatment of moderate to severe pain associated with cancer.

Norgine has an active Research and Development effort and currently has products at various stages of clinical development including NRL994, a bowel preparation product. A European submission and NDA for NRL994 have already been filed.

Norgine has two manufacturing sites; Hengoed in the UK and Dreux, France.

Norgine's website is www.norgine.com

For further information, please contact:

Paul Pay, Vice-President, Business Development, Norgine

T: +44 (0)1895 453710

E: ppay@norgine.com

Louise Blakeborough, Chapter Five

T: +44 (0)1306 731800

E: lblakeborough@chapterfive.co.uk